Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. - Wikidata - awgldk - TriplyDB

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.

http://www.wikidata.org/entity/Q35111932

about

CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas Immunotherapy advances for glioblastoma Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors Engineered T cells for cancer treatment Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.Impact of temozolomide on immune response during malignant glioma chemotherapy A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells Emerging immunotherapies for glioblastoma Prioritization schema for immunotherapy clinical trials in glioblastoma.Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy Design and development of therapies using chimeric antigen receptor-expressing T cells Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Advances in Immunotherapy for Glioblastoma Multiforme.Adoptive immunotherapy for cancer.Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.Genetically modified T cells to target glioblastoma.Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Glioblastoma stem cells and stem cell-targeting immunotherapies.Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.The Dynamics of Interactions Among Immune and Glioblastoma Cells.CAR T-cell immunotherapy: The path from the by-road to the freeway?Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv.Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.Immune and viral therapies for malignant primary brain tumors.Chimeric antigen receptor engineered stem cells: a novel HIV therapy.Engineering Chimeric Antigen Receptors.T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1 Targeting Malignant Brain Tumors with Antibodies.The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis.Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.

P2860

Q26740520-D074E29B-8A76-46DF-BD7C-52ECB47925EE Q26866513-23D871BC-FFC0-45F2-8040-34BA7F39263A Q27011298-12928C05-48E9-4815-87F3-66426F94272E Q33578792-F3A80B75-6CAA-416E-BA53-F2FE7A206B43 Q33606096-CE6EC4EB-8582-450C-8203-49D4CD534F29 Q34177641-79DCB3BC-0DED-4834-8A60-B3CFA2C9AE02 Q36106198-3EEADCED-44F4-4FA9-B0C2-5DCA56A17707 Q36362798-DFA7FE48-A0BA-470C-BF8A-9A201A68ABAB Q36367252-30350791-E648-4482-AE98-73F5724549DB Q36470354-EF811D43-F39B-45D5-B3BA-E4B78EC73161 Q37025105-E69DB5F6-C58B-41EE-BE5D-B87388895248 Q37078999-6B3B6487-0892-4EF5-8065-AA1D4CF1419D Q37185223-1C4B8E93-D820-4A7B-92DC-ECAA1783783E Q37418289-CF8512AF-1C14-4463-935C-993BACD28CE2 Q37609801-16D56F24-BA5F-4421-AD41-047C1E8C3AF8 Q37680966-8C5E933D-37F6-4D1A-A54A-5314522D928F Q38170496-4215D622-49A0-4449-AEED-63E916882AFC Q38170500-94825BBF-E95D-4FB1-8811-CC5A0813EDB5 Q38178690-F5AFC27B-8F81-4699-ADD7-08921F92CD66 Q38203856-334EBC57-FDB0-4A5F-AB19-9E1390B71837 Q38218786-C304D19E-674B-4B6E-96B7-A7E8CEE24957 Q38227889-C3FA4190-B4F0-4AEF-BBFC-DCCF7810348C Q38355702-9A0A0563-4ED5-45F3-A8C4-29B66B527356 Q38435415-3934C076-E009-44A2-ABF9-AD68DC2A67E7 Q38557236-18D6F128-AB63-4961-979F-499D65EE8C92 Q38632105-482B46D0-8F32-4000-BD64-0C220237A6D7 Q38741113-667E2E22-B315-491B-AAA1-F09EA43D9BDF Q38760913-1A5EA8B3-C65E-41F8-ACD0-4939B3E556F0 Q38823847-A3A9048A-E84A-4F1E-A33D-F5DFBADE966F Q38987239-105B4A55-5B79-4DCF-BC0F-9899C639BC51 Q39045586-233F782E-A749-4ECA-99CA-B48331A68467 Q39081204-8F344E9A-B631-4F15-8E01-9C1CBA6ED869 Q39111239-927AABC8-A0CE-487B-82DE-C864277DB223 Q39168899-FA588BBE-10CD-49D2-9199-4968278C10B0 Q39208504-4DA02E4B-3C73-4637-9817-25ABBACB8403 Q39276909-F94A6AFA-E60C-4F00-81FC-0A37092C90DE Q42114926-9F190A6D-FD1A-4074-826A-4A4413D2110B Q42267793-436BFA39-B0D2-46BE-9C99-9D83CA566ED9 Q45918458-A5AB3124-912B-488E-9A59-014CD8519E73 Q47425171-F8906779-C553-4BE0-A56C-0DEFC2179DFD

P2860

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.

http://www.wikidata.org/entity/Q35111932

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Suppression of human glioma xe ...... gen receptor-modified T cells.

@ast

Suppression of human glioma xe ...... gen receptor-modified T cells.

@en

type

label

Suppression of human glioma xe ...... gen receptor-modified T cells.

@ast

Suppression of human glioma xe ...... gen receptor-modified T cells.

@en

prefLabel

Suppression of human glioma xe ...... gen receptor-modified T cells.

@ast

Suppression of human glioma xe ...... gen receptor-modified T cells.

@en

P1433

Q35111932-27FC2610-F17A-479F-88DF-597360609663

P1476

Q35111932-2A2E9C41-D141-49B6-B371-0D90AB682364

P2093

Q35111932-117E7997-3E57-438F-8244-20F0D8474E63

Q35111932-3800C380-F4B9-439C-9700-9472079872F0

Q35111932-6973B01A-7AAA-4E66-B223-B75275D76068

Q35111932-7F6FE52E-4AC7-419B-BF27-F97DEFBC1B2C

Q35111932-93137F03-9F86-4000-BFFA-0D55847AA21E

Q35111932-9DA1FB41-80A6-4DB6-A53A-B027C0211970

Q35111932-B45A2E14-B8E3-41E2-8342-E8B42A328878

Q35111932-B4776611-938E-412C-B717-D61069B4525B

Q35111932-C1A62626-BEC5-4CE2-B179-8B011F002AB0

Q35111932-CB526765-4BE6-4137-BC69-07696FE8BA28

P2860

Q35111932-0ABE7631-89D0-4986-91FA-E190D1A160DC

Q35111932-12854F2A-D36B-4089-B91C-4BF46A6C9011

Q35111932-24F518AC-336A-44D3-8EA0-63B9F2A6C6F9

Q35111932-2E1F5DF1-EBF9-4360-981F-34CB22867594

Q35111932-2F51303F-9F6D-4CE7-9541-90865670D1E3

Q35111932-321C6EBD-F92D-431D-BFA6-52ECDBBA9A3F

Q35111932-37916241-02B8-4C97-A32B-D29DA59B7BF6

Q35111932-4C168F57-0F81-4591-8E3C-4ECD53BD5297

Q35111932-4D97CE98-975F-4517-98B0-562E14125A23

Q35111932-52A85C24-5554-4178-BB56-D291A50F4DD0

P304

Q35111932-82E73B02-E973-41D7-BBCC-22EFEB0BE14C

P31

Q35111932-79692A09-7D05-49B3-A0F1-63A4BE67416D

P356

Q35111932-7A580282-BFA7-4654-B99C-DE66AF60BE5C

P407

Q35111932-CF857652-4BAE-425E-830C-EC348BEDF6B3

P433

Q35111932-8126F89B-5FC0-4B97-ADFF-5D340A16FD04

P478

Q35111932-D088082C-419F-4541-98AE-F465B7E2210B

P577

Q35111932-99A11F3D-D32E-44A4-8B7A-4C79358220EA

P5875

Q35111932-D2D612E2-38D5-4446-B19C-F8DE648A38F6

P698

Q35111932-4990BD0D-EA97-4C2E-8015-B8BF5A58DEDF

P921

Q35111932-787BA1F7-193F-4587-B8FE-C3E647A70DD8

P932

Q35111932-B086EE53-5BEA-4BF7-B4A9-3BDFCE38EF73

P356

1078-0432.CCR-12-0319

P1433

Clinical Cancer Research

P1476

Suppression of human glioma xe ...... gen receptor-modified T cells.

@en

P2093

Anthony J Bais

http://www.w3.org/2001/XMLSchema#string

Ayguen Sahin

http://www.w3.org/2001/XMLSchema#string

Betty Tyler

http://www.w3.org/2001/XMLSchema#string

Bob S Carter

http://www.w3.org/2001/XMLSchema#string

Henry Brem

http://www.w3.org/2001/XMLSchema#string

Jinyuan Zhou

http://www.w3.org/2001/XMLSchema#string

Prakash Sampath

http://www.w3.org/2001/XMLSchema#string

Qiangzhong Ma

http://www.w3.org/2001/XMLSchema#string

Richard P Junghans

http://www.w3.org/2001/XMLSchema#string

Sadhak Sengupta

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system

Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma

Cancer regression in patients after transfer of genetically engineered lymphocytes

Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13

Mutation and functional analysis of IL-13 receptors in human malignant glioma cells

Characterization of the interaction between interleukin-13 and interleukin-13 receptors

cDNA cloning and characterization of the human interleukin 13 receptor alpha chain

Inducible apoptosis as a safety switch for adoptive cell therapy

Quantifying signaling-induced reorientation of T cell receptors during immunological synapse formation.

Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor

P304

5949-5960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-0319

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230830527

http://www.w3.org/2001/XMLSchema#string

P698

22966020

http://www.w3.org/2001/XMLSchema#string

P921

P932

4337849

http://www.w3.org/2001/XMLSchema#string